



19 February 2018

### Exercise of Warrants

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced that it has received notification from a warrant holder to exercise warrants representing 107,142 ordinary shares of 1p each ("Ordinary Shares") in the Company at an exercise price of 32.2p per warrant for total consideration of £34,499.22.

Application has been made for the 107,142 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 22 February 2018. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Following Admission, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 264,097,872 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

For further information, please contact:

<b>Motif Bio plc</b> Graham Lumsden (Chief Executive Officer)	info@motifbio.com
<b>Peel Hunt LLP (NOMAD &amp; BROKER)</b> Dr Christopher Golden Oliver Jackson	+ 44 (0)20 7418 8900
<b>Northland Capital Partners Limited (BROKER)</b> David Hignell/John Howes/ Rob Rees	+44 (0)203 861 6625
<b>Walbrook PR Ltd. (UK FINANCIAL PR &amp; IR)</b> Paul McManus/Helen Cresswell/ Lianne Cawthorne	+44 (0) 20 7933 8780 or motifbio@walbrookpr.com
<b>MC Services AG (EUROPEAN IR)</b> Raimund Gabriel	+49 (0)89 210 2280 raimund.gabriel@mc-services.eu
<b>The Trout Group (US IR)</b> Meggie Purcell	+ 1 (646) 378-2936 mpurcell@troutgroup.com
<b>Russo Partners (US PR)</b> David Schull Travis Kruse, Ph.D.	+1 (858) 717-2310 +1 (212) 845-4272 david.schull@russopartnersllc.com travis.kruse@russopartnersllc.com